Down syndrome (original) (raw)

• Down, J. L. H. Observations on an ethnic classification of idiots. Lond. Hosp. Rep. 3, 259–262 (1866).
  Google Scholar
• Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355, 165–169 (2000).
  Article CAS PubMed Google Scholar
• LeJeune, J., Gautier, M. & Turpin, R. Study of somatic chromosomes from 9 mongoloid children [French]. C. R. Hebd. Seances. Acad. Sci. 248, 1721–1722 (1959). This study is the first description of the chromosomal abnormality in DS.
  CAS PubMed Google Scholar
• Davisson, M. T., Schmidt, C. & Akeson, E. C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. 360, 263–280 (1990).
  CAS PubMed Google Scholar
• Hattori, M. et al. The DNA sequence of human chromosome 21. Nature 405, 311–319 (2000). A landmark paper on the sequencing of the long arm of HSA21.
  Article CAS PubMed Google Scholar
• Antonarakis, S. E. Down syndrome and the complexity of genome dosage imbalance. Nat. Rev. Genet. 18, 147–163 (2017).
  Article CAS PubMed Google Scholar
• Herault, Y. et al. Rodent models in Down syndrome research: impact and future opportunities. Dis. Model. Mech. 10, 1165–1186 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, X. Q. & Mobley, W. C. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses. Front. Neurosci. 13, 446 (2019).
  Article PubMed PubMed Central Google Scholar
• Reeves, R. H. et al. Paving the way for therapy: the Second International Conference of the Trisomy 21 Research Society. Mol. Syndromol. 9, 279–286 (2019).
  Article PubMed Google Scholar
• de Graaf, G., Buckley, F. & Skotko, B. People living with Down syndrome in the USA: births and population. Down Syndrome Education International https://dsuri.net/us-population-factsheet (2019).
• de Graaf, G., Buckley, F. & Skotko, B. G. Estimation of the number of people with Down syndrome in the United States. Genet. Med. 19, 439–447 (2017).
  Article PubMed Google Scholar
• de Graaf, G., Buckley, F. & Skotko, B. G. Birth and population prevalence of Down syndrome in European countries. (Poster presented at the World Down Syndrome Congress 2018).
• Bray, I., Wright, D. E., Davies, C. & Hook, E. B. Joint estimation of Down syndrome risk and ascertainment rates: a meta-analysis of nine published data sets. Prenat. Diagn. 18, 9–20 (1998).
  Article CAS PubMed Google Scholar
• Hecht, C. A. & Hook, E. B. Rates of Down syndrome at livebirth by one-year maternal age intervals in studies with apparent close to complete ascertainment in populations of European origin: a proposed revised rate schedule for use in genetic and prenatal screening. Am. J. Med. Genet. 62, 376–385 (1996).
  Article CAS PubMed Google Scholar
• Hassold, T. & Hunt, P. To err (meiotically) is human: the genesis of human aneuploidy. Nat. Rev. Genet. 2, 280–291 (2001).
  Article CAS PubMed Google Scholar
• Morris, J. K., Wald, N. J., Mutton, D. E. & Alberman, E. Comparison of models of maternal age-specific risk for Down syndrome live births. Prenat. Diagn. 23, 252–258 (2003).
  Article CAS PubMed Google Scholar
• de Graaf, G., Buckley, F. & Skotko, B. G. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am. J. Med. Genet. A 167, 756–767 (2015).
  Article Google Scholar
• Savva, G. M., Morris, J. K., Mutton, D. E. & Alberman, E. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat. Diagn. 26, 499–504 (2006).
  Article PubMed Google Scholar
• Bittles, A. H., Bower, C., Hussain, R. & Glasson, E. J. The four ages of Down syndrome. Eur. J. Public Health 17, 221–225 (2007).
  Article PubMed Google Scholar
• Deng, C. et al. Recent trends in the birth prevalence of Down syndrome in China: impact of prenatal diagnosis and subsequent terminations. Prenat. Diagn. 35, 311–318 (2015).
  Article PubMed Google Scholar
• Morris, J. K. & Alberman, E. Trends in Down’s syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome cytogenetic register. BMJ 339, b3794 (2009).
  Article PubMed PubMed Central Google Scholar
• Tul, N., Verdenik, I., Srsen, T. P. & Antolic, Z. N. P31.05: incidence of Down syndrome in Slovenia in the last 15 years. Ultrasound Obstet. Gynecol. 30, 569–570 (2007).
  Article Google Scholar
• Collins, V. R., Muggli, E. E., Riley, M., Palma, S. & Halliday, J. L. Is Down syndrome a disappearing birth defect? J. Pediatr. 152, 20–24.e1 (2008).
  Article PubMed Google Scholar
• Dolk, H. et al. Trends and geographic inequalities in the prevalence of Down syndrome in Europe, 1980-1999. Rev. Epidemiol Sante Publique 53, 2S87–2S95 (2005).
  Article PubMed Google Scholar
• de Graaf, G. et al. Estimates of live birth prevalence of children with Down syndrome in the period 1991–2015 in the Netherlands. J. Intellect. Disabil. Res. 61, 461–470 (2017).
  Article PubMed Google Scholar
• Nagaoka, S. I., Hassold, T. J. & Hunt, P. A. Human aneuploidy: mechanisms and new insights into an age-old problem. Nat. Rev. Genet. 13, 493–504 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gruhn, J. R. et al. Chromosome errors in human eggs shape natural fertility over reproductive life span. Science 365, 1466–1469 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Antonarakis, S. E. et al. The meiotic stage of nondisjunction in trisomy 21: determination by using DNA polymorphisms. Am. J. Hum. Genet. 50, 544–550 (1992).
  CAS PubMed PubMed Central Google Scholar
• Allen, E. G. et al. Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects. Hum. Genet. 125, 41–52 (2009).
  Article PubMed Google Scholar
• Yoon, P. W. et al. Advanced maternal age and the risk of Down syndrome characterized by the meiotic stage of chromosomal error: a population-based study. Am. J. Hum. Genet. 58, 628–633 (1996).
  CAS PubMed PubMed Central Google Scholar
• Freeman, S. B. et al. The National Down Syndrome Project: design and implementation. Public Health Rep. 122, 62–72 (2007).
  Article PubMed PubMed Central Google Scholar
• Ghosh, S., Feingold, E. & Dey, S. K. Etiology of Down syndrome: evidence for consistent association among altered meiotic recombination, nondisjunction, and maternal age across populations. Am. J. Med. Genet. A 149, 1415–1420 (2009).
  Article CAS Google Scholar
• Oliver, T. R. et al. New insights into human nondisjunction of chromosome 21 in oocytes. PLoS Genet. 4, e1000033 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Chernus, J. M. et al. A candidate gene analysis and GWAS for genes associated with maternal nondisjunction of chromosome 21. PLoS Genet. 15, e1008414 (2019).
  Article PubMed PubMed Central Google Scholar
• Coppede, F. Risk factors for Down syndrome. Arch. Toxicol. 90, 2917–2929 (2016).
  Article CAS PubMed Google Scholar
• Hunter, J. E. et al. The association of low socioeconomic status and the risk of having a child with Down syndrome: a report from the National Down Syndrome Project. Genet. Med. 15, 698–705 (2013).
  Article PubMed PubMed Central Google Scholar
• Torfs, C. P. & Christianson, R. E. Socioeconomic effects on the risk of having a recognized pregnancy with Down syndrome. Birth Defects Res. A Clin. Mol. Teratol. 67, 522–528 (2003).
  Article CAS PubMed Google Scholar
• Christianson, R. E., Sherman, S. L. & Torfs, C. P. Maternal meiosis II nondisjunction in trisomy 21 is associated with maternal low socioeconomic status. Genet. Med. 6, 487–494 (2004).
  Article PubMed Google Scholar
• Ghosh, S., Ghosh, P. & Dey, S. K. Altered incidence of meiotic errors and Down syndrome birth under extreme low socioeconomic exposure in the Sundarban area of India. J. Community Genet. 5, 119–124 (2014).
  Article PubMed Google Scholar
• Keen, C. et al. The association between maternal occupation and Down syndrome: a report from the national Down syndrome project. Int. J. Hyg. Environ. Health 223, 207–213 (2020).
  Article CAS PubMed Google Scholar
• Sartain, C. V. & Hunt, P. A. An old culprit but a new story: bisphenol A and "NextGen" bisphenols. Fertil. Steril. 106, 820–826 (2016).
  Article PubMed PubMed Central Google Scholar
• Horan, T. S. et al. Replacement bisphenols adversely affect mouse gametogenesis with consequences for subsequent generations. Curr. Biol. 28, 2948–2954.e3 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Grandjean, P. et al. Timescales of developmental toxicity impacting on research and needs for intervention. Basic Clin. Pharmacol. Toxicol. 125, 70–80 (2019).
  Article CAS PubMed Google Scholar
• Antonarakis, S. E., Avramopoulos, D., Blouin, J. L., Talbot, C. C. Jr. & Schinzel, A. A. Mitotic errors in somatic cells cause trisomy 21 in about 4.5% of cases and are not associated with advanced maternal age. Nat. Genet. 3, 146–150 (1993).
  Article CAS PubMed Google Scholar
• Antonarakis, S. E. Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. Down Syndrome Collaborative Group. N. Engl. J. Med. 324, 872–876 (1991). This paper reports the use of DNA polymorphic markers to determine the parental origin of the supernumerary HSA21 in DS.
  Article CAS PubMed Google Scholar
• Antonarakis, S. E. 10 years of genomics, chromosome 21, and Down syndrome. Genomics 51, 1–16 (1998).
  Article CAS PubMed Google Scholar
• Morris, J. K., Alberman, E., Mutton, D. & Jacobs, P. Cytogenetic and epidemiological findings in Down syndrome: England and Wales 1989-2009. Am. J. Med. Genet. A 158, 1151–1157 (2012).
  Article Google Scholar
• Lyle, R. et al. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur. J. Hum. Genet. 17, 454–466 (2009).
  Article CAS PubMed Google Scholar
• Barlow, G. M. et al. Down syndrome congenital heart disease: a narrowed region and a candidate gene. Genet. Med. 3, 91–101 (2001).
  Article CAS PubMed Google Scholar
• Gupta, M., Dhanasekaran, A. R. & Gardiner, K. J. Mouse models of Down syndrome: gene content and consequences. Mamm. Genome 27, 538–555 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Epstein, C. J. et al. Protocols to establish genotype-phenotype correlations in Down syndrome. Am. J. Hum. Genet. 49, 207–235 (1991).
  CAS PubMed PubMed Central Google Scholar
• Bray, I. C. & Wright, D. E. Estimating the spontaneous loss of Down syndrome fetuses between the times of chorionic villus sampling, amniocentesis and livebirth. Prenat. Diagn. 18, 1045–1054 (1998).
  Article CAS PubMed Google Scholar
• Hassold, T. J. & Jacobs, P. A. Trisomy in man. Ann.Rev.Genet. 18, 69–97 (1984).
  Article CAS PubMed Google Scholar
• Shapiro, B. L. Down syndrome – a disruption of homeostasis. Am. J. Med. Genet. 14, 241–269 (1983).
  Article CAS PubMed Google Scholar
• Pritchard, M. & Kola, I. The ‘gene dosage effect’ hypothesis versus the ‘amplified developmental instability’ hypothesis in Down syndrome. J. Neural Transm. 57, 293–303 (1999).
  CAS Google Scholar
• Stamoulis, G. et al. Single cell transcriptome in aneuploidies reveals mechanisms of gene dosage imbalance. Nat. Commun. 10, 4495 (2019).
  Article PubMed PubMed Central CAS Google Scholar
• Salehi, A. et al. Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29–42 (2006). A study that provided support for the hypothesis that neuronal degeneration in DS is due to increased APP expression.
  Article CAS PubMed Google Scholar
• Pelleri, M. C. et al. Integrated quantitative transcriptome maps of human trisomy 21 tissues and cells. Front. Genet. 9, 125 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Sullivan, K. D. et al. Trisomy 21 consistently activates the interferon response. eLife 5, e16220 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Gonzales, P. K. et al. Transcriptome analysis of genetically matched human induced pluripotent stem cells disomic or trisomic for chromosome 21. PLoS One 13, e0194581 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Letourneau, A. et al. Domains of genome-wide gene expression dysregulation in Down’s syndrome. Nature 508, 345–350 (2014).
  Article CAS PubMed Google Scholar
• Do, C., Xing, Z., Yu, Y. E. & Tycko, B. Trans-acting epigenetic effects of chromosomal aneuploidies: lessons from Down syndrome and mouse models. Epigenomics 9, 189–207 (2017).
  Article CAS PubMed Google Scholar
• Do, L. H., Mobley, W. C. & Singhal, N. Questioned validity of gene expression dysregulated domains in Down’s syndrome. F1000Res. 4, 269 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Ahlfors, H. et al. Gene expression dysregulation domains are not a specific feature of Down syndrome. Nat. Commun. 10, 2489 (2019).
  Article PubMed PubMed Central Google Scholar
• Umlauf, D. & Mourad, R. The 3D genome: from fundamental principles to disease and cancer. Semin. Cell Dev. Biol. 90, 128–137 (2019).
  Article CAS PubMed Google Scholar
• Kemeny, S. et al. Spatial organization of chromosome territories in the interphase nucleus of trisomy 21 cells. Chromosoma 127, 247–259 (2018).
  Article CAS PubMed Google Scholar
• Mendioroz, M. et al. Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down syndrome and mouse models. Genome Biol. 16, 263 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• El Hajj, N. et al. Epigenetic dysregulation in the developing Down syndrome cortex. Epigenetics 11, 563–578 (2016).
  Article PubMed PubMed Central Google Scholar
• Horvath, S. et al. Accelerated epigenetic aging in Down syndrome. Aging Cell 14, 491–495 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Scott, H. S. et al. Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 48, 330–340 (1998).
  Article CAS PubMed Google Scholar
• Xiao, C. L. et al. N6-methyladenine DNA modification in the human genome. Mol. Cell 71, 306–318.e7 (2018).
  Article CAS PubMed Google Scholar
• Kim, I. S. et al. Roles of Mis18α in epigenetic regulation of centromeric chromatin and CENP-A loading. Mol. Cell 46, 260–273 (2012).
  Article CAS PubMed Google Scholar
• Veland, N. et al. DNMT3L facilitates DNA methylation partly by maintaining DNMT3A stability in mouse embryonic stem cells. Nucleic Acids Res. 47, 152–167 (2019).
  Article CAS PubMed Google Scholar
• Lu, J. et al. Global hypermethylation in fetal cortex of Down syndrome due to DNMT3L overexpression. Hum. Mol. Genet. 25, 1714–1727 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sailani, M. R. et al. DNA-methylation patterns in trisomy 21 using cells from monozygotic twins. PLoS One 10, e0135555 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Guo, X., Williams, J. G., Schug, T. T. & Li, X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J. Biol. Chem. 285, 13223–13232 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lepagnol-Bestel, A. M. et al. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Hum. Mol. Genet. 18, 1405–1414 (2009).
  Article CAS PubMed Google Scholar
• Liu, Y. et al. Systematic proteome and proteostasis profiling in human trisomy 21 fibroblast cells. Nat. Commun. 8, 1212 (2017). First quantitative study of the trisomy 21 proteome, using fibroblasts from individuals with DS.
  Article PubMed PubMed Central CAS Google Scholar
• Gillet, L. C. et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell Proteom. 11, O111.016717 (2012).
  Article CAS Google Scholar
• Sullivan, K. D. et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci. Rep. 7, 14818 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5, e15004 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Izzo, A. et al. Mitochondrial dysfunction in Down syndrome: molecular mechanisms and therapeutic targets. Mol. Med. 24, 2 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Zamponi, E. & Helguera, P. R. The shape of mitochondrial dysfunction in Down syndrome. Dev. Neurobiol. 79, 613–621 (2019).
  Article CAS PubMed Google Scholar
• Valenti, D. et al. Mitochondria as pharmacological targets in Down syndrome. Free. Radic. Biol. Med. 114, 69–83 (2018).
  Article CAS PubMed Google Scholar
• Vilardell, M. et al. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 12, 229 (2011).
  Article PubMed PubMed Central Google Scholar
• Reeves, R. et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11, 177–183 (1995). This paper describes the first complex model of trisomy 21, Ts65Dn, and lays out characterizations for comparing the effects of aneuploidy in mice and humans.
  Article CAS PubMed Google Scholar
• Sussan, T., Yang, A., Li, F., Ostrowski, M. & Reeves, R. H. Trisomy protects against ApcMin-mediated tumors in mouse models of Down syndrome. Nature 451, 73–75 (2008).
  Article CAS PubMed Google Scholar
• Garcia-Cerro, S., Rueda, N., Vidal, V., Lantigua, S. & Martinez-Cue, C. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer’s disease phenotypes. Neurobiol. Dis. 106, 76–88 (2017).
  Article CAS PubMed Google Scholar
• Aziz, N. M. et al. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome. Disease Models Mech 11, dmm031013 (2018).
  Article CAS Google Scholar
• Gribble, S. M. et al. Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome. PLoS One 8, e60482 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kazuki, Y. et al. A non-mosaic humanized mouse model of Down syndrome, trisomy of a nearly complete long arm of human chromosome 21 in mouse chromosome background. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/862433v1 (2019).
• Ramirez-Solis, R., Liu, P. & Bradley, A. Chromosome engineering in mice. Nature 378, 720–724 (1995).
  Article CAS PubMed Google Scholar
• Olson, L. E., Richtsmeier, J. T., Leszl, J. & Reeves, R. H. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306, 687–690 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, T. et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum. Mol. Genet. 19, 2780–2791 (2010). This paper reports a mouse model that is trisomic for all mouse chromosomal regions syntenic with HSA21.
  Article CAS PubMed PubMed Central Google Scholar
• Stefanidis, K. et al. Causes of infertility in men with Down syndrome. Andrologia 43, 353–357 (2011).
  Article CAS PubMed Google Scholar
• Williams, B. R. et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322, 703–709 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Contestabile, A. et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 17, 665–678 (2007).
  Article PubMed Google Scholar
• Kleschevnikov, A. M. et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153–8160 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Siarey, R. J., Stoll, J., Rapoport, S. I. & Galdzicki, Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology 36, 1549–1554 (1997).
  Article CAS PubMed Google Scholar
• Ferencz, C. et al. Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J. Pediatr. 114, 79–86 (1989).
  Article CAS PubMed Google Scholar
• Lana-Elola, E. et al. Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel. eLife 5, e11614 (2016).
  Article PubMed PubMed Central Google Scholar
• Li, H. et al. Penetrance of congenital heart disease in a mouse model of Down syndrome depends on a trisomic potentiator of a disomic modifier. Genetics 203, 763–770 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Edie, S. et al. Survey of human chromosome 21 gene expression effects on early development in Danio rerio. G3 8, 2215–2223 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, Q., Rasmussen, S. A. & Friedman, J. M. Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359, 1019–1025 (2002).
  Article PubMed Google Scholar
• Escorihuela, R. M. et al. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 199, 143–146 (1995).
  Article CAS PubMed Google Scholar
• Holtzman, D. M. et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl Acad. Sci. USA 93, 13333–13338 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Hanson, J. E., Blank, M., Valenzuela, R. A., Garner, C. C. & Madison, D. V. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down’s syndrome. J. Physiol. 579, 53–67 (2007). This study establishes the imbalance between excitatory and inhibitory inputs in the hippocampus, which has been the focus of efforts to antagonize signalling through GABA-A receptors, including a trial to improve cognitive ability in individuals with DS (NCT01436955).
  Article CAS PubMed Google Scholar
• Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411–413 (2007). One of the first mouse studies that raised the possibility of pharmacotherapy for the cognitive impairment in DS.
  Article CAS PubMed Google Scholar
• Braudeau, J. et al. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol (2011).
• Duchon, A. et al. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist. Br. J. Pharmacol. https://doi.org/10.1111/bph.14903 (2019).
• Hart, S. J. et al. Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: strides to date. Am. J. Med. Genet. A 173, 3029–3041 (2017).
  Article PubMed Google Scholar
• de la Torre, R. et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 801–810 (2016). A successful randomized trial to improve cognitive functioning in young adults with DS.
  Article PubMed CAS Google Scholar
• Jack, C. R. Jr. et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Esparza, T. J. et al. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104–119 (2013).
  Article CAS PubMed Google Scholar
• Strydom, A. et al. Alzheimer’s disease in Down syndrome: an overlooked population for prevention trials. Alzheimers Dement. 4, 703–713 (2018).
  Google Scholar
• Thonberg, H. et al. Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient. BMC Res. Notes 4, 476 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wallon, D. et al. The French series of autosomal dominant early onset Alzheimer’s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J. Alzheimers Dis. 30, 847–856 (2012).
  Article CAS PubMed Google Scholar
• Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24–26 (2006). This study provides strong evidence for a link between the triplication of APP in trisomy 21 and early-onset AD in individuals with DS.
  Article CAS PubMed Google Scholar
• Sleegers, K. et al. APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain 129, 2977–2983 (2006).
  Article PubMed Google Scholar
• Wiseman, F. K. et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 16, 564–574 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Doran, E. et al. Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. J. Alzheimers Dis. 56, 459–470 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Ryoo, S. R. et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease. J. Neurochem. 104, 1333–1344 (2008).
  Article CAS PubMed Google Scholar
• Wegiel, J. et al. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol. 113, 389–402 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Vingtdeux, V. et al. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol. Dis. 20, 625–637 (2005).
  Article CAS PubMed Google Scholar
• Woods, Y. L. et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bε at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609–615 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Lindwall, G. & Cole, R. D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301–5305 (1984).
  CAS PubMed Google Scholar
• LaPointe, N. E. et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 87, 440–451 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Goedert, M. & Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739, 240–250 (2005).
  Article CAS PubMed Google Scholar
• Liu, F. et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 22, 3224–3233 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yin, X. et al. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice. Sci. Rep. 7, 619 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Chen, X. Q., Sawa, M. & Mobley, W. C. Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. Free Radic. Biol. Med. 114, 52–61 (2018).
  Article CAS PubMed Google Scholar
• Stenmark, H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10, 513–525 (2009).
  Article CAS PubMed Google Scholar
• Roberts, R. L. et al. Endosome fusion in living cells overexpressing GFP-rab5. J. Cell Sci. 112, 3667–3675 (1999).
  CAS PubMed Google Scholar
• Cataldo, A. et al. Endocytic disturbances distinguish among subtypes of Alzheimer’s disease and related disorders. Ann. Neurol. 50, 661–665 (2001).
  Article CAS PubMed Google Scholar
• Cataldo, A. M., Barnett, J. L., Pieroni, C. & Nixon, R. A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J. Neurosci. 17, 6142–6151 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Cataldo, A. M. et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277–286 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Corlier, F. et al. Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer’s disease patients. Transl. Psychiatry 5, e595 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Saunders, A. M. et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467–1472 (1993).
  Article CAS PubMed Google Scholar
• Rohn, T. T., McCarty, K. L., Love, J. E. & Head, E. Is apolipoprotein E4 an important risk factor for dementia in persons with Down syndrome? J. Parkinsons Dis. Alzheimers Dis. 1, 7 (2014).
  PubMed PubMed Central Google Scholar
• Cataldo, A. M. et al. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 173, 370–384 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Cossec, J. C. et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum. Mol. Genet. 21, 3156–3172 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Nuriel, T. et al. The endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo. Front. Neurosci. 11, 702 (2017).
  Article PubMed PubMed Central Google Scholar
• Xu, W. et al. Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J. Clin. Invest. 126, 1815–1833 (2016).
  Article PubMed PubMed Central Google Scholar
• Jiang, Y. et al. Alzheimer’s-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl Acad. Sci. USA 107, 1630–1635 (2010).
  Article CAS PubMed Google Scholar
• Jiang, Y. et al. Lysosomal dysfunction in Down syndrome is APP-dependent and mediated by APP-βCTF (C99). J. Neurosci. 39, 5255–5268 (2019).
  Article PubMed PubMed Central Google Scholar
• Kwart, D. et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, not Aβ. Neuron 104, 256–270.e1–e5 (2019).
  Article CAS PubMed Google Scholar
• Cuckle, H. & Maymon, R. Development of prenatal screening – a historical overview. Semin. Perinatol. 40, 12–22 (2016).
  Article PubMed Google Scholar
• Bianchi, D. W., Crombleholme, T. M., D’Alton M. E. & Malone, F. D. Fetology: Diagnosis and Management of the Fetal Patient Ch. 131 (McGraw-Hill Medical, 2010).
• Bianchi, D. W., Rava, R. P. & Sehnert, A. J. DNA sequencing versus standard prenatal aneuploidy screening. N. Engl. J. Med. 371, 577–578 (2014).
  Article Google Scholar
• Norton, M. E. & Wapner, R. J. Cell-free DNA analysis for noninvasive examination of trisomy. N. Engl. J. Med. 373, 2581–2582 (2015).
  Article Google Scholar
• Bianchi, D. W. & Chiu, R. W. K. Sequencing of circulating cell-free DNA during pregnancy. N. Engl. J. Med. 379, 464–473 (2018).
  Article CAS PubMed Google Scholar
• Liu, S. et al. Genomic analyses from non-invasive prenatal testing reveal genetic associations, patterns of viral infections, and Chinese population history. Cell 175, 347–359.e14 (2018).
  Article CAS PubMed Google Scholar
• Taylor-Phillips, S. et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 6, e010002 (2016).
  Article PubMed PubMed Central Google Scholar
• Hill, M. et al. Has noninvasive prenatal testing impacted termination of pregnancy and live birth rates of infants with Down syndrome? Prenat. Diagn. 37, 1281–1290 (2017).
  Article PubMed PubMed Central Google Scholar
• Ralston, S. J., Wertz, D., Chelmow, D., Craigo, S. D. & Bianchi, D. W. Pregnancy outcomes after prenatal diagnosis of aneuploidy. Obstet. Gynecol. 97, 729–733 (2001).
  CAS PubMed Google Scholar
• Alexander, M. et al. Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Dev. Med. Child. Neurol. 58, 246–254 (2016).
  Article PubMed Google Scholar
• Bull, M. J. & Committee on Genetics,. Health supervision for children with Down syndrome. Pediatrics 128, 393–406 (2011).
  Article PubMed Google Scholar
• Jensen, K. M. & Bulova, P. D. Managing the care of adults with Down’s syndrome. BMJ 349, g5596 (2014).
  Article PubMed CAS Google Scholar
• Capone, G. et al. Co-occurring medical conditions in adults with Down syndrome: a systematic review toward the development of health care guidelines. Am. J. Med. Genet. A 176, 116–133 (2018).
  Article PubMed Google Scholar
• Roizen, N. J. & Patterson, D. Down’s syndrome. Lancet 361, 1281–1289 (2003).
  Article PubMed Google Scholar
• Glasson, E. J., Dye, D. E. & Bittles, A. H. The triple challenges associated with age-related comorbidities in Down syndrome. J. Intellect. Disabil. Res. 58, 393–398 (2014).
  Article CAS PubMed Google Scholar
• Bergstrom, S. et al. Trends in congenital heart defects in infants with Down syndrome. Pediatrics 138, e20160123 (2016).
  Article PubMed Google Scholar
• Morales-Demori, R. Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome. Congenit. Heart Dis. 12, 820–827 (2017).
  Article PubMed Google Scholar
• Russell, M. W., Chung, W. K., Kaltman, J. R. & Miller, T. A. Advances in the understanding of the genetic determinants of congenital heart disease and their impact on clinical outcomes. J. Am. Heart Assoc. 7, e006906 (2018).
  Article PubMed PubMed Central Google Scholar
• Churchill, S. S., Kieckhefer, G. M., Landis, C. A. & Ward, T. M. Sleep measurement and monitoring in children with Down syndrome: a review of the literature, 1960–2010. Sleep. Med. Rev. 16, 477–488 (2012).
  Article PubMed PubMed Central Google Scholar
• Smith, D. S. Health care management of adults with Down syndrome. Am. Fam. Physician 64, 1031–1039 (2001).
  CAS PubMed Google Scholar
• Esbensen, A. J., Hoffman, E. K., Stansberry, E. & Shaffer, R. Convergent validity of actigraphy with polysomnography and parent reports when measuring sleep in children with Down syndrome. J. Intellect. Disabil. Res. 62, 281–291 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Hill, C. M. et al. Home oximetry to screen for obstructive sleep apnoea in Down syndrome. Arch. Dis. Child. 103, 962–967 (2018).
  Article PubMed Google Scholar
• Venekamp, R. P. et al. Tonsillectomy or adenotonsillectomy versus non-surgical management for obstructive sleep-disordered breathing in children. Cochrane Database Syst. Rev. 10, CD011165 (2015).
  Google Scholar
• Purdy, I. B., Singh, N., Brown, W. L., Vangala, S. & Devaskar, U. P. Revisiting early hypothyroidism screening in infants with Down syndrome. J. Perinatol. 34, 936–940 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Iughetti, L., Lucaccioni, L., Fugetto, F., Mason, A. & Predieri, B. Thyroid function in Down syndrome. Expert Rev. Endocrinol. Metab. 10, 525–532 (2015).
  Article CAS PubMed Google Scholar
• Sarici, D. et al. Thyroid functions of neonates with Down syndrome. Ital. J. Pediatr. 38, 44 (2012).
  Article PubMed PubMed Central Google Scholar
• Hardy, O. et al. Hypothyroidism in Down syndrome: screening guidelines and testing methodology. Am. J. Med. Genet. A 124, 436–437 (2004).
  Article Google Scholar
• Bittles, A. H. & Glasson, E. J. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev. Med. Child. Neurol. 46, 282–286 (2004).
  Article CAS PubMed Google Scholar
• Hithersay, R. et al. Association of dementia with mortality among adults with Down syndrome older than 35 years. JAMA Neurol. 76, 152–160 (2019). This paper identifies AD as the most prominent cause of mortality in adults with DS.
  Article PubMed Google Scholar
• Strydom, A. et al. Dementia in older adults with intellectual disabilities—epidemiology, presentation, and diagnosis. J. Policy Pract. Intellect. Disabil. 7, 96–110 (2010).
  Article Google Scholar
• Ballard, C., Mobley, W., Hardy, J., Williams, G. & Corbett, A. Dementia in Down’s syndrome. Lancet Neurol. 15, 622–636 (2016).
  Article PubMed Google Scholar
• Bayen, E., Possin, K. L., Chen, Y., Cleret de Langavant, L. & Yaffe, K. Prevalence of aging, dementia, and multimorbidity in older adults with Down syndrome. JAMA Neurol. 75, 1399–1406 (2018).
  Article PubMed PubMed Central Google Scholar
• Lott, I. T. & Head, E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat. Rev. Neurol. 15, 135–147 (2019).
  Article PubMed PubMed Central Google Scholar
• Startin, C. M. et al. Cognitive markers of preclinical and prodromal Alzheimer’s disease in Down syndrome. Alzheimers Dement. 15, 245–257 (2019).
  Article PubMed PubMed Central Google Scholar
• Firth, N. C. et al. Aging related cognitive changes associated with Alzheimer’s disease in Down syndrome. Ann. Clin. Transl. Neurol. 5, 741–751 (2018).
  Article PubMed PubMed Central Google Scholar
• De Simone, R., Puig, X. S., Gelisse, P., Crespel, A. & Genton, P. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer’s disease in Down syndrome. Seizure 19, 383–389 (2010).
  Article PubMed Google Scholar
• Royal College of Psychiatrists & The British Psychological Society. Dementia and People with Intellectual Disabilities: Guidance on the assessment, diagnosis, interventions and support of people with intellectual disabilities who develop dementia. https://www.dsrf.org/media/REP77%20final%20proof%20(3).pdf (The British Psychological Society, 2015).
• Eady, N. et al. Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study. Br. J. Psychiatry 212, 155–160 (2018).
  Article PubMed Google Scholar
• Livingstone, N., Hanratty, J., McShane, R. & Macdonald, G. Pharmacological interventions for cognitive decline in people with Down syndrome. Cochrane Database Syst. Rev. 10, CD011546 (2015).
  Google Scholar
• Dodd, K. et al. Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support. Aging Mental Health 22, 1406–1415 (2018).
  Article PubMed Google Scholar
• Sanmaneechai, O. et al. Treatment outcomes of West syndrome in infants with Down syndrome. Pediatric Neurol. 48, 42–47 (2013).
  Article Google Scholar
• Gholipour, T., Mitchell, S., Sarkis, R. A. & Chemali, Z. The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy. Epilepsy Behav. 68, 11–16 (2017).
  Article PubMed Google Scholar
• Austeng, M. E. et al. Otitis media with effusion in children with in Down syndrome. Int. J. Pediatr Otorhinolaryngol. 77, 1329–1332 (2013).
  Article PubMed Google Scholar
• Fisher, P. G. Congenital hearing loss in Down syndrome. J. Pediatr. 166, 1–3 (2015).
  Article Google Scholar
• Shott, S. R., Joseph, A. & Heithaus, D. Hearing loss in children with Down syndrome. Int. J. Pediatr. Otorhinolaryngol. 61, 199–205 (2001).
  Article CAS PubMed Google Scholar
• Krinsky-McHale, S. J. et al. Vision deficits in adults with Down syndrome. J. Appl. Res. Intellect. Disabil. 27, 247–263 (2014).
  Article PubMed Google Scholar
• Li, E. Y., Chan, T. C., Lam, N. M. & Jhanji, V. Cataract surgery outcomes in adult patients with Down’s syndrome. Br. J. Ophthalmol. 98, 1273–1276 (2014).
  Article PubMed Google Scholar
• Brockmeyer, D. Down syndrome and craniovertebral instability. Topic review and treatment recommendations. Pediatr. Neurosurg. 31, 71–77 (1999).
  Article CAS PubMed Google Scholar
• Capone, G., Goyal, P., Ares, W. & Lannigan, E. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am. J. Med. Genet. C 142, 158–172 (2006).
  Article Google Scholar
• Mantry, D. et al. The prevalence and incidence of mental ill-health in adults with Down syndrome. J. Intellect. Disabil. Res. 52, 141–155 (2008).
  CAS PubMed Google Scholar
• Tassé, M. J. et al. Psychiatric conditions prevalent among adults with Down syndrome. J. Policy Pract. Intellect. Disabil. 13, 173–180 (2016).
  Article Google Scholar
• Mircher, C. et al. Acute regression in young people with Down syndrome. Brain Sci. 7, 57 (2017).
  Article PubMed Central Google Scholar
• Spendelow, J. S. Assessment of mental health problems in people with Down syndrome: key considerations. Br. J. Learn. Disabil. 39, 306–313 (2011).
  Article Google Scholar
• Nevill, R. E. & Benson, B. A. Risk factors for challenging behaviour and psychopathology in adults with Down syndrome. J.Intellect. Disabil. Res. 62, 941–951 (2018).
  Article CAS PubMed Google Scholar
• Liogier d’Ardhuy, X. et al. Assessment of cognitive scales to examine memory, executive function and language in individuals with Down syndrome: implications of a 6-month observational study. Front. Behav. Neurosci. 9, 300 (2015).
  Article PubMed PubMed Central Google Scholar
• Dykens, E. M. Psychiatric and behavioral disorders in persons with Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 13, 272–278 (2007).
  Article PubMed Google Scholar
• Aman, M. G., Buican, B. & Arnold, L. E. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J. Child. Adolesc. Psychopharmacol. 13, 29–40 (2003).
  Article PubMed Google Scholar
• Guedj, F., Bianchi, D. W. & Delabar, J. M. Prenatal treatment of Down syndrome: a reality? Curr. Opin. Obstet. Gynecol. 26, 92–103 (2014).
  Article PubMed Google Scholar
• Bianchi, D. W. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat. Med. 18, 1041–1051 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Stagni, F., Giacomini, A., Emili, M., Guidi, S. & Bartesaghi, R. Neurogenesis impairment: an early developmental defect in Down syndrome. Free. Radic. Biol. Med. 114, 15–32 (2018).
  Article CAS PubMed Google Scholar
• Guidi, S. et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol. 18, 180–197 (2008).
  Article PubMed Google Scholar
• Guidi, S., Ciani, E., Bonasoni, P., Santini, D. & Bartesaghi, R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. Brain Pathol. 21, 361–373 (2011).
  Article PubMed Google Scholar
• Dierssen, M. & de Lagran, M. M. DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis. ScientificWorldJournal 6, 1911–1922 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Tarui, T. et al. Quantitative MRI analyses of regional brain growth in living fetuses with Down syndrome. Cereb. Cortex. https://doi.org/10.1093/cercor/bhz094 (2019).
  Article PubMed Central Google Scholar
• Stagni, F., Giacomini, A., Guidi, S., Ciani, E. & Bartesaghi, R. Timing of therapies for Down syndrome: the sooner, the better. Front. Behav. Neurosci. 9, 265 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• de Wert, G., Dondorp, W. & Bianchi, D. W. Fetal therapy for Down syndrome: an ethical exploration. Prenat. Diagn. 37, 222–228 (2017).
  Article PubMed Google Scholar
• Incerti, M. et al. Prenatal treatment prevents learning deficit in Down syndrome model. PLoS One 7, e50724 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kelley, C. M. et al. Effects of maternal choline supplementation on the septohippocampal cholinergic system in the Ts65Dn mouse model of Down syndrome. Curr. Alzheimer Res. 13, 84–96 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• McElyea, S. D. et al. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome. Hum. Mol. Genet. 25, 4856–4869 (2016).
  CAS PubMed PubMed Central Google Scholar
• Nakano-Kobayashi, A. et al. Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice. Proc. Natl Acad. Sci. USA 114, 10268–10273 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Izzo, A. et al. Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells. Hum. Mol. Genet. 26, 1056–1069 (2017).
  CAS PubMed Google Scholar
• Guidi, S. et al. Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model. Brain 137, 380–401 (2014).
  Article PubMed Google Scholar
• Gao, S. Y. et al. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. Br. J. Clin. Pharmacol. 83, 2134–2147 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, M. et al. The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: a systematic review and meta-analysis. J. Glob. Health 7, 020413 (2017).
  Article PubMed PubMed Central Google Scholar
• Grut, V., Söderström, L. & Naumburg, E. National cohort study showed that infants with Down’s syndrome faced a high risk of hospitalisation for the respiratory syncytial virus. Acta Paediatr. 106, 1519–1524 (2017).
  Article PubMed Google Scholar
• Bloemers, B. L. P. et al. Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect. 12, 799–808 (2010).
  Article CAS PubMed Google Scholar
• Giménez-Barcons, M. et al. Autoimmune predisposition in Down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens. J. Immunol. 193, 3872–3879 (2014).
  Article PubMed CAS Google Scholar
• Swigonski, N. L., Kuhlenschmidt, H. L., Bull, M. J., Corkins, M. R. & Downs, S. M. Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma. Pediatrics 118, 594–602 (2006).
  Article PubMed Google Scholar
• Tunstall, O. et al. Guidelines for the investigation and management of transient leukaemia of Down syndrome. Br. J. Haematol. 182, 200–211 (2018).
  Article PubMed Google Scholar
• Mateos, M. K., Barbaric, D., Byatt, S.-A., Sutton, R. & Marshall, G. M. Down syndrome and leukemia: insights into leukemogenesis and translational targets. Transl. Pediatr. 4, 76–92 (2015).
  PubMed PubMed Central Google Scholar
• Gamis, A. S. & Smith, F. O. Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder. Br. J. Haematol. 159, 277–287 (2012).
  Article PubMed Google Scholar
• Skotko, B. G., Levine, S. P., Macklin, E. A. & Goldstein, R. D. Family perspectives about Down syndrome. Am. J. Med. Genet. A 170, 930–941 (2016).
  Article Google Scholar
• Van Herwegen, J., Ashworth, M. & Palikara, O. Parental views on special educational needs provision: cross-syndrome comparisons in Williams syndrome, Down syndrome, and autism spectrum disorders. Res. Dev. Disabil. 80, 102–111 (2018).
  Article PubMed Google Scholar
• Buckley, S., Bird, G., Sacks, B. & Archer, T. A comparison of mainstream and special education for teenagers with Down syndrome: implications for parents and teachers. Syndrome Res. Pract. 9, 54–67 (2006).
  Article Google Scholar
• Kumin, L. & Schoenbrodt, L. Employment in adults with Down syndrome in the United States: results from a national survey. Appl. Res. Intellect. Disabil. 29, 330–345 (2015).
  Article Google Scholar
• Mihaila, I. et al. Leisure activity and caregiver involvement in middle-aged and older adults with Down syndrome. Intellect. Dev. Disabil. 55, 97–109 (2017).
  Article PubMed PubMed Central Google Scholar
• Xanthopoulos, M. S. et al. Caregiver-reported quality of life in youth with Down syndrome. J. Pediatr. 189, 98–104.e1 (2017).
  Article PubMed PubMed Central Google Scholar
• Diaz, K. M. Physical inactivity among parents of children with and without Down syndrome: the National Health Interview Survey. J. Intellect. Disabil. Res. 64, 38–44 (2020).
  Article CAS PubMed Google Scholar
• Hardee, J. P. & Fetters, L. The effect of exercise intervention on daily life activities and social participation in individuals with Down syndrome: a systematic review. Res. Dev. Disabil. 62, 81–103 (2017).
  Article CAS PubMed Google Scholar
• O’Roak, B. J. et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338, 1619–1622 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Becker, W., Soppa, U. & Tejedor, F. J. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. CNS Neurol. Disord. Drug Targets 13, 26–33 (2014).
  Article CAS PubMed Google Scholar
• Mowery, C. T. et al. Trisomy of a Down syndrome critical region globally amplifies transcription via HMGN1 overexpression. Cell Rep. 25, 1898–1911.e5 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Tanay, A. & Regev, A. Scaling single-cell genomics from phenomenology to mechanism. Nature 541, 331–338 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Annus, T. et al. The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis. Neurobiol. Aging 53, 11–19 (2017). Describes the age of onset of amyloid deposition in the brain of individuals with DS using PET imaging.
  Article CAS PubMed PubMed Central Google Scholar
• Rafii, M. S. Tau PET imaging for staging of Alzheimer’s disease in Down syndrome. Dev. Neurobiol. 79, 711–715 (2019).
  Article PubMed Google Scholar
• Fortea, J. et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 17, 860–869 (2018). Explores age-related changes in fluid biomarkers associated with AD in individuals with DS to show similarities with sporadic AD.
  Article CAS PubMed Google Scholar
• Strydom, A. et al. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimer’s Res. Ther. 10, 39 (2018).
  Article CAS Google Scholar
• Xiao, M. F. et al. NPTX2 and cognitive dysfunction in Alzheimer’s disease. eLife 6, e23798 (2017).
  Article PubMed PubMed Central Google Scholar
• Rafii, M. S. et al. Plasma neurofilament light and Alzheimer’s disease biomarkers in Down syndrome: results from the Down syndrome biomarker initiative (DSBI). J. Alzheimers Dis. 70, 131–138 (2019).
  Article CAS PubMed Google Scholar
• Das, I. & Reeves, R. H. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis. Model.Mech. 4, 596–606 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Duchon, A. et al. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm. Genome 22, 674–684 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Reinholdt, L. et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm. Genome 22, 685–691 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kanekiyo, T., Xu, H. & Bu, G. ApoE and Aβ in Alzheimer’s disease: accidental encounters or partners? Neuron 81, 740–754 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Startin, C. M. et al. The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Res. 1, 11 (2016).
  Article PubMed PubMed Central Google Scholar
• Sinai, A. et al. Predictors of age of diagnosis and survival of Alzheimer’s disease in Down syndrome. J. Alzheimers Dis. 61, 717–728 (2018).
  Google Scholar